Curis, Inc. (CRIS) Stock Score, Valuation & Financial Research
Curis, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 16/100.
Quick answer for CRIS
Curis, Inc. currently has a Wall Street Score of 16/100. The stored market price is $1.12. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is +0.3 points. These figures are a research snapshot, not a buy or sell recommendation.
What Curis, Inc. does
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche L
CRIS financial snapshot
- Wall Street Score:
- 16/100
- Current price:
- $1.12
- Market capitalization:
- $2.2M
- Revenue:
- $4.3M
- Net income:
- $-21.2M
- Free cash flow:
- $-27.2M
- Cash:
- $5.6M
- Total debt:
- $1.0M
- EPS:
- -14.22
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 20/100
What stands out
- Reported year-over-year revenue growth is -0.5%.
- Free cash flow is $-27.2M, showing cash burn in the current stored period.
- The balance sheet shows $5.6M of cash versus $1.0M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.3 points: CRIS increased 0.3 points because Revenue improved by 3.4 points.
- The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-17.
How to research CRIS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.